Walleye Capital LLC Takes Position in IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 386,183 shares of the company’s stock, valued at approximately $14,393,000.

Several other institutional investors have also recently made changes to their positions in the business. Strs Ohio bought a new position in IDEAYA Biosciences in the 4th quarter worth approximately $868,000. Profund Advisors LLC raised its position in shares of IDEAYA Biosciences by 127.7% during the fourth quarter. Profund Advisors LLC now owns 47,115 shares of the company’s stock valued at $1,629,000 after buying an additional 26,424 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of IDEAYA Biosciences by 1.1% during the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock valued at $242,023,000 after buying an additional 78,797 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of IDEAYA Biosciences in the first quarter worth $2,875,000. Finally, Wesbanco Bank Inc. lifted its holdings in shares of IDEAYA Biosciences by 87.3% in the fourth quarter. Wesbanco Bank Inc. now owns 39,700 shares of the company’s stock worth $1,372,000 after buying an additional 18,500 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Insider Transactions at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total transaction of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is currently owned by insiders.

IDEAYA Biosciences Price Performance

Shares of IDYA opened at $36.30 on Friday. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -18.71 and a beta of -0.10. IDEAYA Biosciences, Inc. has a 1 year low of $23.23 and a 1 year high of $40.58. The business’s 50 day simple moving average is $35.19 and its 200-day simple moving average is $32.71.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the prior year, the company posted ($0.88) earnings per share. The firm’s revenue was up 8800.0% compared to the same quarter last year. On average, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on IDYA shares. Wall Street Zen lowered shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Royal Bank Of Canada reduced their price target on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a report on Tuesday, July 7th. Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Friday, July 17th. Finally, Truist Financial dropped their price objective on shares of IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.12.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.